KALV · KalVista Pharmaceuticals, Inc.

Current Thesis

KALV is a near-closed cash takeout, not a tradeable narrative. Chiesi Group is acquiring KalVista at $27.00/share all-cash (~$1.9B equity value, 36% premium to the 30-day VWAP as of 2026-04-28) via a subsidiary tender (Skyline Merger Sub) that expires 2026-06-10, 11:59pm ET. As of this refresh the deal is essentially de-risked: all three antitrust/FDI gates have cleared US HSR waiting period expired 2026-05-28, Germany's FCO declined to meet GWB prohibition criteria 2026-05-27, and the Italian FDI authority confirmed no objection 2026-05-29. The sole remaining condition is the minimum-tender (majority of ~53.24M shares outstanding). Stock trades ~$26.66, a ~$0.34 / ~1.3% spread to the $27.00 cash price. Every dollar of the narrative first oral on-demand HAE therapy, EKTERLY launch is already monetized into the bid. pass. Merger-arb tail, zero momentum leg, delisting imminent.

Bull Case

• Deal is now mechanically near-certain. With HSR (expired 2026-05-28), Germany GWB (cleared 2026-05-27), and Italy FDI (no objection 2026-05-29) all done, the only open item is the majority-tender condition due 2026-06-10. An all-cash strategic deal at a 36% premium with both boards unanimous and regulators cleared rarely fails the tender step.
• Underlying asset justifies the bid. EKTERLY (sebetralstat) booked ~$49M FY2025 net revenue (~$35M in Q4 2025 alone), with 1,702 patient start forms, ~20% US HAE penetration, and 724 prescribers through 2026-02-28, plus Japan (Kaken), Germany and UK launches in 2026 a real revenue floor under the price, lowering walk-away odds.
• Arb math (for a dedicated arb book only): ~1.3% over a sub-week tender window into a regulatory-clean close annualizes attractively but this is not an arb book.
• Topping-bid optionality (low probability): the only first-mover oral on-demand HAE asset is scarce; no competing bidder has surfaced as of 2026-06-07.

Bear Case

• Inverted asymmetry for a momentum book: ~$0.34 (1.3%) of capped upside to $27.00 vs ~$11 (~40%) of downside on a deal-break reversion to ~$15-16. Pennies in front of a (now nearly stopped) steamroller.
• No momentum signal exists. The stock gapped to the deal zone on 2026-04-29 (the announcement-day +39% pop) and has flatlined just under $27 since. RSI, 20-EMA and breakout reads are noise on a deal-pinned tape; there is no trend or velocity to catch.
• Capital trap with a hard expiry. Sizing here parks book capital for a sub-2% capped return into imminent delisting while accelerating-narrative names run elsewhere the documented alpha leak in this playbook.
• Sell-side has already stepped aside. H.C. Wainwright cut KALV to Neutral on the merger a standard de-rating that confirms there is no equity story left to trade, only deal mechanics.
• the ticker disappears.

Setup & Price Structure

• Price (latest): ~$26.66. Deal price: $27.00. Spread: ~$0.34 / ~1.3%.
• 52-wk range: $9.83 $26.98. The stock is glued to the top of the range because of the bid, not momentum.
• Shares outstanding: 53,240,888 (as of 2026-05-06). Equity deal value ~$1.9B incl. options/dilution.
• Structure read: Flat-line pin just under the cash offer; volatility is dead until the tender result. Moving-average and RSI interpretation does not apply to an M&A-pinned name. Rule-engine caution: this ticker will trip "price at/near 52-wk high, above all MAs" breakout rules with zero momentum edge treat any such trigger as M&A-pinned and ignore.

Catalyst Calendar (next 30 days)

• 2026-06-10 (11:59pm ET): Tender offer expiration. Majority-tender condition is the only open gate; all regulatory conditions already satisfied. Expect either confirmation of a successful tender (→ second-step merger, delisting within days) or a short extension if tender count is light.
• ~2026-06-11 to mid-June (est.): Likely 8-K / SC TO-T/A reporting tender results and percentage of shares tendered; merger close can follow promptly now that antitrust/FDI is clear (faster than the original "Q3 2026" placeholder).
• No earnings event relevant the standalone business is being absorbed; no call will move a deal-pinned price.

What Would Change Our Mind

A standalone re-rating only re-opens on a deal-break: tender fails the minimum (majority) condition by 2026-06-10 with no extension, or the merger agreement is terminated, or price closes below $25 (spread blowout signaling break risk). Any of these reverts KALV toward the ~$15-16 standalone level (52-wk low $9.83) only then, on a fresh base with a re-established narrative (EKTERLY ramp re-pricing as an independent), would this become a momentum candidate again. The only upside reset above the pin is a competing bid >$27.00, for which there is no evidence as of 2026-06-07. Absent a break or a topping bid, the correct action stays pass through delisting.

Correlation Notes

• Idiosyncratic / deal-driven: KALV's price is decoupled from biotech beta (XBI), rate moves, and HAE-peer tape it tracks the Chiesi deal probability, not sector flow. A broad biotech selloff would not move a cleared cash pin.
• Peer read-through is muted: other HAE/rare-disease names (e.g. broader bradykinin-pathway and on-demand HAE plays) are unaffected by this specific takeout closing; do not infer theme acceleration from KALV's chart it is a single-name M&A artifact, not a momentum signal for the precision-therapeutics theme.
• Deal-break contagion (low odds): a surprise termination would hit KALV alone, not the theme; it would, however, briefly widen perceived regulatory risk on other pending rare-disease cash deals.